Cybin (HELP) Competitors

Cybin logo
$6.78 -0.11 (-1.60%)
Closing price 04:00 PM Eastern
Extended Trading
$6.84 +0.06 (+0.90%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HELP vs. RGC, PBH, PRGO, HRMY, and TRVI

Should you buy Cybin stock or one of its competitors? Cybin's main competitors and comparable companies include Regencell Bioscience (RGC), Prestige Consumer Healthcare (PBH), Perrigo (PRGO), Harmony Biosciences (HRMY), and Trevi Therapeutics (TRVI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cybin compare to Regencell Bioscience?

Cybin (NASDAQ:HELP) and Regencell Bioscience (NASDAQ:RGC) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Regencell Bioscience's return on equity of 0.00% beat Cybin's return on equity.

Company Net Margins Return on Equity Return on Assets
CybinN/A -91.67% -85.59%
Regencell Bioscience N/A N/A N/A

In the previous week, Cybin had 11 more articles in the media than Regencell Bioscience. MarketBeat recorded 11 mentions for Cybin and 0 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 0.00 beat Cybin's score of -0.05 indicating that Regencell Bioscience is being referred to more favorably in the news media.

Company Overall Sentiment
Cybin Neutral
Regencell Bioscience Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CybinN/AN/A-$148M-$3.04N/A
Regencell BioscienceN/AN/A-$11.70MN/AN/A

17.9% of Cybin shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 15.0% of Cybin shares are held by insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cybin presently has a consensus price target of $47.33, indicating a potential upside of 586.99%. Given Cybin's stronger consensus rating and higher probable upside, equities analysts plainly believe Cybin is more favorable than Regencell Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cybin
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Regencell Bioscience
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Cybin has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market.

Summary

Cybin beats Regencell Bioscience on 6 of the 11 factors compared between the two stocks.

How does Cybin compare to Prestige Consumer Healthcare?

Cybin (NASDAQ:HELP) and Prestige Consumer Healthcare (NYSE:PBH) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

In the previous week, Cybin had 9 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 11 mentions for Cybin and 2 mentions for Prestige Consumer Healthcare. Prestige Consumer Healthcare's average media sentiment score of 0.25 beat Cybin's score of -0.05 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cybin
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Prestige Consumer Healthcare
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Prestige Consumer Healthcare has a net margin of 13.29% compared to Cybin's net margin of 0.00%. Prestige Consumer Healthcare's return on equity of 11.28% beat Cybin's return on equity.

Company Net Margins Return on Equity Return on Assets
CybinN/A -91.67% -85.59%
Prestige Consumer Healthcare 13.29%11.28%5.25%

Cybin currently has a consensus price target of $47.33, suggesting a potential upside of 586.99%. Prestige Consumer Healthcare has a consensus price target of $67.00, suggesting a potential upside of 32.59%. Given Cybin's stronger consensus rating and higher probable upside, equities analysts plainly believe Cybin is more favorable than Prestige Consumer Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cybin
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Prestige Consumer Healthcare
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

17.9% of Cybin shares are held by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 15.0% of Cybin shares are held by company insiders. Comparatively, 1.5% of Prestige Consumer Healthcare shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cybin has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

Prestige Consumer Healthcare has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CybinN/AN/A-$148M-$3.04N/A
Prestige Consumer Healthcare$1.09B2.20$190.30M$3.2415.60

Summary

Prestige Consumer Healthcare beats Cybin on 8 of the 14 factors compared between the two stocks.

How does Cybin compare to Perrigo?

Perrigo (NYSE:PRGO) and Cybin (NASDAQ:HELP) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

In the previous week, Cybin had 9 more articles in the media than Perrigo. MarketBeat recorded 11 mentions for Cybin and 2 mentions for Perrigo. Perrigo's average media sentiment score of 0.28 beat Cybin's score of -0.05 indicating that Perrigo is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Perrigo
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cybin
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cybin has a net margin of 0.00% compared to Perrigo's net margin of -43.27%. Perrigo's return on equity of 12.39% beat Cybin's return on equity.

Company Net Margins Return on Equity Return on Assets
Perrigo-43.27% 12.39% 4.07%
Cybin N/A -91.67%-85.59%

Perrigo currently has a consensus price target of $18.50, suggesting a potential upside of 8.82%. Cybin has a consensus price target of $47.33, suggesting a potential upside of 586.99%. Given Cybin's stronger consensus rating and higher possible upside, analysts clearly believe Cybin is more favorable than Perrigo.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Perrigo
2 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.83
Cybin
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

95.9% of Perrigo shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 0.4% of Perrigo shares are owned by insiders. Comparatively, 15.0% of Cybin shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cybin has lower revenue, but higher earnings than Perrigo. Cybin is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Perrigo$4.09B0.58-$1.43B-$12.76N/A
CybinN/AN/A-$148M-$3.04N/A

Perrigo has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market. Comparatively, Cybin has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

Summary

Cybin beats Perrigo on 8 of the 14 factors compared between the two stocks.

How does Cybin compare to Harmony Biosciences?

Cybin (NASDAQ:HELP) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

In the previous week, Harmony Biosciences had 4 more articles in the media than Cybin. MarketBeat recorded 15 mentions for Harmony Biosciences and 11 mentions for Cybin. Harmony Biosciences' average media sentiment score of 0.17 beat Cybin's score of -0.05 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cybin
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Harmony Biosciences
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

17.9% of Cybin shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 11.0% of Harmony Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Harmony Biosciences has a net margin of 18.05% compared to Cybin's net margin of 0.00%. Harmony Biosciences' return on equity of 18.55% beat Cybin's return on equity.

Company Net Margins Return on Equity Return on Assets
CybinN/A -91.67% -85.59%
Harmony Biosciences 18.05%18.55%13.24%

Harmony Biosciences has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CybinN/AN/A-$148M-$3.04N/A
Harmony Biosciences$989.36M1.97$158.69M$3.0210.96

Cybin presently has a consensus target price of $47.33, indicating a potential upside of 586.99%. Harmony Biosciences has a consensus target price of $48.00, indicating a potential upside of 44.97%. Given Cybin's stronger consensus rating and higher possible upside, equities research analysts plainly believe Cybin is more favorable than Harmony Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cybin
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Harmony Biosciences
1 Sell rating(s)
6 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.38

Cybin has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.

Summary

Harmony Biosciences beats Cybin on 10 of the 13 factors compared between the two stocks.

How does Cybin compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Cybin (NASDAQ:HELP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 15.4% of Trevi Therapeutics shares are held by insiders. Comparatively, 15.0% of Cybin shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevi TherapeuticsN/AN/A-$42.76M-$0.39N/A
CybinN/AN/A-$148M-$3.04N/A

In the previous week, Cybin had 4 more articles in the media than Trevi Therapeutics. MarketBeat recorded 11 mentions for Cybin and 7 mentions for Trevi Therapeutics. Cybin's average media sentiment score of -0.05 beat Trevi Therapeutics' score of -0.38 indicating that Cybin is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Trevi Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cybin
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Trevi Therapeutics' return on equity of -24.81% beat Cybin's return on equity.

Company Net Margins Return on Equity Return on Assets
Trevi TherapeuticsN/A -24.81% -23.96%
Cybin N/A -91.67%-85.59%

Trevi Therapeutics currently has a consensus price target of $28.09, indicating a potential upside of 107.93%. Cybin has a consensus price target of $47.33, indicating a potential upside of 586.99%. Given Cybin's stronger consensus rating and higher probable upside, analysts plainly believe Cybin is more favorable than Trevi Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trevi Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.92
Cybin
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

Trevi Therapeutics has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Cybin has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

Summary

Trevi Therapeutics beats Cybin on 9 of the 13 factors compared between the two stocks.

Get Cybin News Delivered to You Automatically

Sign up to receive the latest news and ratings for HELP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HELP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HELP vs. The Competition

MetricCybinPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$541.11M$13.12B$7.47B$11.44B
Dividend YieldN/A2.59%2.47%4.64%
P/E Ratio-2.2327.5632.7729.51
Price / SalesN/A7.498.005.30
Price / CashN/A15.5920.8521.62
Price / Book1.515.294.383.65
Net Income-$148M$2.87B$3.51B$394.00M
7 Day Performance-23.48%-5.84%-6.16%-6.39%
1 Month Performance-36.58%-6.83%-7.05%-8.77%
1 Year PerformanceN/A-7.91%-2.52%-8.47%

Cybin Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HELP
Cybin
3.9995 of 5 stars
$6.78
-1.6%
$47.33
+598.1%
N/A$541.11MN/AN/A100
RGC
Regencell Bioscience
0.3857 of 5 stars
$4.55
-3.6%
N/A-64.2%$2.34BN/AN/A10
PBH
Prestige Consumer Healthcare
3.4541 of 5 stars
$48.17
+0.4%
$67.00
+39.1%
-14.7%$2.28B$1.09B14.87890
PRGO
Perrigo
2.2875 of 5 stars
$15.81
-2.3%
$18.50
+17.0%
+26.6%$2.25B$4.25BN/A8,100
HRMY
Harmony Biosciences
4.3049 of 5 stars
$33.01
+0.2%
$48.00
+45.4%
-2.6%$1.94B$868.45M10.91293

Related Companies and Tools


This page (NASDAQ:HELP) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners